← All indications
Virus Diseases
A general term for diseases caused by viruses.
Subtype terms (16)
More specific conditions that are subtypes of Virus Diseases in the MeSH hierarchy.
- Arbovirus Infections
1 drug experimental
- Bronchiolitis, Viral
6 drugs (5 approved, 1 experimental)
- Central Nervous System Viral Diseases
1 drug experimental
- DNA Virus Infections
6 drugs (5 approved, 1 experimental)
- Eye Infections, Viral
- Hepatitis, Viral, Animal
- Hepatitis, Viral, Human
10 drugs (5 approved, 5 experimental)
- Pneumonia, Viral
74 drugs (46 approved, 28 experimental)
- Reticuloendotheliosis, Avian
- RNA Virus Infections
28 drugs (11 approved, 17 experimental)
- Sexually Transmitted Diseases, Viral
14 drugs (7 approved, 7 experimental)
- Skin Diseases, Viral
1 drug approved
- Slow Virus Diseases
- Tumor Virus Infections
7 drugs (6 approved, 1 experimental)
- Viral Zoonoses
- Viremia
11 drugs (8 approved, 3 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (21)
- vitamin e
- bacille calmette-guerin
- duloxetine
- nifedipine
- enalapril
- entecavir
- tacrolimus
- inactivated rabies vaccine
- cyclosporine
- everolimus
- inactivated influenza vaccine
- tick-borne encephalitis vaccine
- superoxide dismutase
- metoprolol
- lansoprazole
- prednisolone
- tenofovir alafenamide
- omega-3 fatty acids
- baloxavir marboxil
- interferon alpha-2b
- ubiquinone
Phase 3 trials (32)
- hydroxychloroquine
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- ritonavir
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- mepolizumab
- menitorix
- menjugate
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- rabies vaccine (purified chick embryo cell vaccine)
- lopinavir
- rabies immune globulin (human)
- rotavirus vaccine, live, oral, pentavalent
- cyclophosphamide
- bevacizumab
- syn023
- tocilizumab
- Anti-thymocyte Globulin (Rabbit)
- influenza vlp vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Tozorakimab
- hypochlorous acid
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- hexavalent pneumococcal polysaccharide vaccine
- anakinra
- telbivudine
- salvia
- COVID-19 convalescent plasma
- thymbra
- +2 more
Phase 2 trials (46)
- metformin
- allostim
- theophylline
- maraviroc
- cantharidin
- cetylpyridinium chloride
- danirixin
- gsk3390107a
- glycerin
- chlorine dioxide
- flulaval
- omalizumab
- oseltamivir
- aluminum hydroxide
- sulfamethoxazole
- gla-se
- enoxaparin
- uprifosbuvir
- vapendavir
- yellow fever vaccine 17d strain
- inactivated japanese encephalitis vaccine
- mva-bn-filo
- ad26.zebov
- autologous dc-vaccines
- influenza vaccine, recombinant hemagglutinin
- live attenuated chimeric japanese encephalitis vaccine
- multi-virus-specific cytotoxic t lymphocytes
- vrc-pbspla043-00-vp
- vrc-zkadna090-00-vp
- azithromycin
- +16 more
Phase 1 trials (19)
- fvh1
- zanamivir
- Rilematovir
- uv-4b
- cmv/ebv specific t-cell
- h6n1 teal hk 97/aa ca recombinant vaccine
- live influenza a vaccine h7n3 (6-2) aa ca recombinant (a/chicken/british columbia/cn-6/2004 x a/ann arbor/6/60 ca)
- mf59
- mva-bn
- cow/human parainfluenza virus vaccine
- rhpiv1 84/del170/942a
- rhpiv3cp45
- gsk3903133a
- vee vlp
- partially hla-matched virus specific t cells
- norovirus -specific t-cell
- Lufotrelvir
- cov2 sam
- a/mallard/ohio-99/mm4/1989 h10n7
Organizations
Organization Involved with Phase 4 Indications (60)
- University of Barcelona
- Vanderbilt University
- University of Western Ontario
- Schering-Plough
- University of Virginia
- University of Maryland
- Medical University of South Carolina
- National Taiwan University
- Bristol-Myers Squibb
- University of Alberta
- Lower Saxony Center for Nephrology
- National Institute on Drug Abuse (NIDA)
- Regeneron
- University of Athens
- Canadian Institutes of Health Research (CIHR)
- Cairo University
- Dalhousie University
- Gottfried Wilhelm Leibniz Universität Hannover
- Centre Hospitalier Universitaire de la Réunion
- University of Manitoba
- Gilead Sciences
- Hellenic Institute for the Study of Sepsis
- Merck
- ZRT Laboratory
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of California, San Francisco
- Medical University of Vienna
- University of Paris
- Providence Health & Services
- Yonsei University
- +30 more
Organization Involved with Phase 3 Indications (122)
- Government of Sierra Leone
- Beni Suef University
- The EMMES Corporation
- Ark Biosciences Inc.
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
- University of Minnesota
- University of Melbourne
- Abbott
- Chiltern International
- Karolinska Institute
- National Institute for Research in Tuberculosis, Chennai, India
- University of Kinshasa
- Novavax
- Vertex
- Bill and Melinda Gates Foundation
- French National Agency for Research on AIDS and Viral Hepatitis
- Egyptian Liver Hospital
- Telethon Kids Institute
- Chinese Academy of Medical Sciences
- Indian Council of Medical Research
- University of Bordeaux
- Icahn School of Medicine at Mount Sinai
- National Cancer Institute (NCI)
- Xintong Pharmacy Company
- Chang Gung University
- Public Health England
- National Institutes of Health (NIH)
- The Netherlands Asthma Foundation
- Sanofi
- Hebrew University
- +92 more
Organization Involved with Phase 2 Indications (187)
- Government of the Republic of Guinea
- Medical University of Graz
- Duke University
- Beijing Institute of Biotechnology
- ABF Pharmaceutical Services GmbH
- Southern Medical University
- SRI International
- University of Pennsylvania
- VGX Pharmaceuticals, LLC
- Justus Liebig University Giessen
- Danderyds Hospital
- Shin Nippon Biomedical Laboratories
- Children's National Medical Center
- MacroGenics
- Inovio Pharmaceuticals
- Celularity, Inc.
- Kitasato University
- National Marrow Donor Program
- ZymoGenetics
- University of Rochester
- Eastern Cooperative Oncology Group
- Eiger BioPharmaceuticals
- Auckland Clinical Studies
- CytoPharm, Inc.
- German Cancer Research Center
- The Parker Institute
- Oclassen
- University of Bern
- Regional Clinical Research
- Government of Liberia
- +157 more
Organization Involved with Phase 1 Indications (86)
- Presidio Pharmaceuticals
- China Immunotech
- Cerus Corporation
- Tysana Pte Ltd
- Canadian Science Centre for Human and Animal Health
- Government of Chile
- University of Geneva
- Mucosis BV
- Genzyme
- Syneos Health
- National University of Singapore
- Codagenix, Inc
- IQVIA
- Mahidol University
- Optimal Research
- Albert Schweitzer Hospital
- Philipps University of Marburg
- Arbutus Biopharma Corporation
- Department of Defense
- Makerere University
- SL BIGEN
- Health Sciences Centre Foundation, Manitoba
- University of Oklahoma
- Erciyes University
- MicroDose
- Taipei Veteran General hospital
- Q-Pharm
- Harmony Clinical Research
- Pennsylvania State University
- Oklahoma Medical Research Foundation
- +56 more
Organization Involved with Other Experimental Indications (23)
- Sprim Consulting
- Uppsala University
- The Research Grants Council, Hong Kong
- University of Southern Denmark
- University of Edinburgh
- Naestved Hospital
- Central South University
- Rockefeller University
- Thrasher Research Fund
- University of Health Sciences Lahore
- St. Joseph's Children's Hospital of Tampa
- Eastern Virginia Medical School
- Indiana University
- European Union
- NHS Lothian
- Glaxo Wellcome
- Jiao Tong University
- Chulalongkorn University
- Fonterra Research Centre
- Imperial College London
- University of South Florida
- Daiwa Pharmaceutical Corporation
- Beijing Kawin Technology Share-Holding Co., Ltd.